# data[].attributes.body
According to the CDC, heart disease is the number one cause of death in United States (U.S.) among all ethnicities. Accounting for almost one in every four deaths, and affecting more men than women.
The Mayo Clinic explains, that the most common cause of cardiac arrest is an arrhythmia called ventricular fibrillation.
Ventricular fibrillation is characterized by rapid erradic electrical impulses causing the ventricles to quiver uselessly instead of pumping blood.
As a critical care nurse for more than 21 years, I have witnessed the devastating effects of heart disease and cardiac arrhythmias.
Other cardiac arrhythmias are also detrimental without early detection or treatment. Ventricular tachycardia, Supra-ventricular tachycardia, third degree heart block, and bradycardia  are some examples of cardiac arrhythmias. When early detection tools are available, the chances for survival increases

# data[].attributes.headline
Abott's  Insertable Cardiac Monitor (ICM) 2017

# data[].attributes.subject
Abott's  Insertable Cardiac Monitor (ICM) 2017

# data[].attributes.body
According to sjm.com Abbot's Insertable cardiac monitor is the world's first continuous heart monitor that is compatible with smartphones.
The ICM combines a smartphone app and integrated symptom recorder to make monitor the heart rhythm easy, effective and discreet.

# data[].attributes.body
1. Early recognition of cardiac arrhythmias.
2. Eliminates the need for a bedside transmitter and separate activator to record symptoms.
3. Continuous monitor using the patient's smartphone to record episodes of irregular heart beat.
4. Transmission of cardiac rhythm information and symptoms to care providers, allowing early recognition and prevention of cardiac arrest.

# data[].attributes.body
1. Requires invasive procedure for insertion.
2. Patient can experience allergic reactions, bleeding, nerve damage, erosion, excessive fibrotic tissue growth, formation of hematoma, keloid formation and migration.
3. There is risk for infection.

# data[].attributes.body
Retrived from sjm.com

# data[].attributes.body
Retrieved from https://2nznub4x5d61ra4q12fyu67t-wpengine.netdna-ssl.com/wp-content/uploads/2017/05/abbott-monitoring.jpg

# data[].attributes.body
Abbott's Insertable ICD is a very important early detection tool for patients and healthcare providers. With heart disease being the leading cause of death in the U.S. is imperative that the patients experiencing cardiac symptoms and/or arrhythmias have the ability to share crucial information with their health care providers, this will help prevent and treat heart conditions that can lead to sudden cardiac death.
This current innovation will provide access to healthcare providers to information with a touch of a button in a smartphone. Early detection and intervention will be a key factor in saving lives.

# data[].attributes.body
1. Angelica - Analytical.
I choose Angelica because she likes to challenge people. The analytical person like to find reliable data to prove their theories.
Strenghtsfinder 2.0
2. Carter - Communication
Because of the ability to bring events to life, energized them and make them exciting and vivid. Strengthsfinder 2.0
3. Daisy - Developer is always in a lookout for the signs of growth and she fuels from them.
Strengthsfinder 2.0
4. Daniel - Discipline
I choose him because of the predictability of his actions. He focus on timeliness and deadlines.
Strenghtfinder 2.0
5. Randall - Responsibility
He take ownership for anything he commits too. because for him quitting is not an option.
Strenghtsfinder 2.0

# data[].attributes.body
Abbot launches the first and only smartphone compatible insertable cardiac monitor in the U.S. (2017). Retrieved from abbott.mediaroom.com

Heart disease facts and statistics. (2017). Retrieved from cdc.gov

Rath, T. (2017). Strengtfinder 2.0 Discover your Discover your CliftonStrenths : GALLUP PRESS.

Heart Arrhythmia. (2018). Retrieved from mayoclinic.org

# data[].attributes.attachment_link.readable_text
With the launch of the Confirm Rx ICM in European CE Mark countries, Abbott has established a new paradigm in the connectivity of cardiac devices by incorporating wireless technology, which allows the ICM to communicate directly and securely to the app downloaded onto a patient's smartphone. Traditional remote monitoring has required bulky handheld or bedside transmitters, which limit patient mobility. The new interactive myMerlin mobile app replaces these passive transmitters and empowers patients to participate in their own care.

In addition to patient convenience, the device is slimmer than currently available ICMs. The Confirm Rx ICM also offers intuitive one-touch indication-based programming, and remote monitoring via the Merlin.net™ Patient Care Network, making the technology convenient for clinicians involved in procedure and follow up.

"The Confirm Rx ICM device will be an important tool for diagnosing patients with suspected arrhythmias, such as those who have experienced fainting or palpitations," said Georg Nölker, M.D., head of electrophysiology at the Herz-und Diabeteszentrum NRW, Ruhr-University of Bad Oeynhausen, Germany. Dr. Nölker was one of the first physicians to implant the Confirm Rx ICM after it received CE Mark. "The simple insertion procedure and small device size make this technology convenient for both patients and providers. Patients can record symptoms directly on their smartphone without the need for a bedside transmitter or separate activator."

Christopher Piorkowski, M.D., head of the Department of Electrophysiology at the University of Dresden Heart Center in Dresden, Germany, and one of the first implanters, added: "The Confirm Rx ICM will be particularly useful in monitoring for atrial fibrillation in my patients with paroxysmal AF, following AF ablation and with stroke of an unknown cause. It allows an objective way to quantify AF events to guide treatment decisions. The smartphone compatibility engages patients and allows better compliance to remote monitoring through a simple and intuitive user interface. This allows clinic staff to reduce follow-up burden and focus on reviewing transmitted data for AF."

The myMerlin mobile app, available in over 35 languages, makes it easy for patients to stay connected to their physicians. Patients can record their symptoms on their own smartphone and specify events such as fainting or if they experience a fast heart rate. Patients can also confirm their data was transmitted to their physician and get automatic alerts when they have missed a scheduled transmission, saving the clinic from having to follow up with the patient. The device also offers secure transmission of patient data. Recently, Abbott's Merlin.net Patient Care Network received one of the medical device industry's first Service Organization Control certifications (SOC2 certification), further confirming the safety and security of the company's remote monitoring network.

"Incorporating wireless technology directly into our devices enhances the quality of remote monitoring and patient compliance," said Mark D. Carlson, M.D., chief medical officer of Abbott's cardiac arrhythmias and neuromodulation businesses. "The Confirm Rx ICM addresses a broad range of indications, such as syncope, palpitations and atrial fibrillation. The technology has been designed with robust data privacy and security measures to ensure peace of mind for both patients and providers."

Currently the Confirm Rx ICM is available in select countries in Europe, with full European release expected during the second quarter of 2017. The device is currently under review by the U.S. Food and Drug Administration. The estimated 2017 worldwide insertable cardiac monitor market is approximately $800 million and is growing by more than $100 million a year.

About Abbott:
At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.

Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.

SOURCE Abbott

Related Links

# data[].attributes.attachment_link.title
Abbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor

# data[].attributes.attachment_link.description
With the launch of the Confirm Rx ICM in European CE Mark countries, Abbott has established a new paradigm in the connectivity of cardiac devices by incorporating wireless technology, which allows the ICM to communicate directly and securely to the app downloaded onto a patient's smartphone.